학술논문
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
Document Type
article
Author
Surbhi Sidana; Lauren C. Peres; Hamza Hashmi; Hitomi Hosoya; Christopher Ferreri; Jack Khouri; Danai Dima; Shebli Atrash; Peter Voorhees; Gary Simmons; Douglas W. Sborov; Nilesh Kalariya; Vanna Hovanky; Sushma Bharadwaj; David Miklos; Charlotte Wagner; Mehmet H. Kocoglu; Gurbakhash Kaur; James A. Davis; Shonali Midha; Murali Janakiram; Ciara Freeman; Melissa Alsina; Frederick Locke; Rebecca Gonzalez; Yi Lin; Joseph McGuirk; Aimaz Afrough; Leyla Shune; Krina K. Patel; Doris K. Hansen
Source
Haematologica, Vol 109, Iss 3 (2023)
Subject
Language
English
ISSN
0390-6078
1592-8721
1592-8721
Abstract
We evaluated patients with relapsed multiple myeloma with renal impairment (RI) treated with standard of care idecabtagene vicleucel (ide-cel), as outcomes with chimeric antigen receptor (CAR) T-cell therapy are unknown in this population. RI was defined as creatinine clearance (CrCl)